Lulizumab pegol

Lulizumab pegol
Monoclonal antibody
Type ?
Source Humanized
Target glycoprotein CD28
Clinical data
ATC code none
CAS Number 1421830-13-8
ChemSpider none
Chemical and physical data
Formula C552H859N149O164S4
Molar mass 52 kg/mol

Lulizumab pegol[1] is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]

This drug was developed by Bristol-Myers Squibb.


  1. World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol, American Medical Association.
This article is issued from Wikipedia - version of the 2/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.